Please assess the completion status of the following clinical trial:

Trial Title: Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 8 years to 17 years~* Non-Ambulatory (unable to complete 10m run/walk under 10s)~* Weight \</=100Kg~* Diagnosis of DMD confirmed by at least one the following:~  * Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, or~ * Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, or~ * Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with DMD, with a typical clinical picture of DMD, or~ * Positive family history of DMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of DMD.~* Cardiac ejection fraction \>55% on echocardiogram~* Use of nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility has been discontinued at least 4 weeks prior to screening (daily multivitamin use is acceptable).~* Glucocorticoid therapy, if used, must have a stable weight-based dose for at least 3 months prior to enrollment~* Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor antagonists (e.g.~spironolactone, eplerenone, etc.), and/or beta-blocker therapy, and must be stable for 3 months prior to enrollment.~* Hematology profile within normal range.~* Baseline laboratory safety chemistry profile within typical range for DMD (elevated ALT / AST acceptable in the absence of elevated GGT, elevated CK acceptable).~Exclusion Criteria:~* Inability to complete cardiac or strength, range of motion and mobility assessments per protocol~* Current enrollment in another treatment clinical trial.~* History of significant concomitant illness or significant impairment of renal or hepatic function.~* Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.~* Cardiac symptoms that, in the opinion of the investigator, may be suggestive of imminent moderate to severe cardiac events, irrespective of LVEF.

- Gender: MALE
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 8-weeks open-label (+)- Epicatechin at 25mg/day twice per day,
- Cohort 2 (Type: EXPERIMENTAL): 8-weeks open-label (+)- Epicatechin at 25mg/day three times per day
- Cohort 3 (Type: EXPERIMENTAL): 8-weeks open-label (+)- Epicatechin at 75mg/day at two times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).